REPL Replimune (REPL) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001737953
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
145
13F, latest reported quarter
What the filings say about REPL
Insiders, 180 days
-$1.6M net sold
6 sellers · 0% of sales under a 10b5-1 plan
Replimune insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Replimune Group, Inc. insiders sold a net $1.6M of stock across 104 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Aug 10, 2026.
- The trade is 4.3% of the 215,852 shares held after it.
- 3 other insiders sold within 30 days.
- 145 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Hill Emily Luisa sold about $132.2K of REPL on Aug 17, 2026; 3 other insiders sold within 30 days and 145 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on May 18, 2026.
- The trade is 7.7% of the 99,425 shares held after it.
- 3 other insiders sold within 30 days.
- 145 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Accounting Officer Schwendenman Andrew sold about $99.0K of REPL on Aug 10, 2026; 3 other insiders sold within 30 days and 145 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on May 18, 2026.
- The trade is 5.1% of the 224,215 shares held after it.
- 3 other insiders sold within 30 days.
- 145 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Xynos Konstantinos sold about $148.5K of REPL on Aug 10, 2026; 3 other insiders sold within 30 days and 145 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on May 18, 2026.
- The trade is 5.1% of the 225,108 shares held after it.
- 3 other insiders sold within 30 days.
- 145 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Hill Emily Luisa sold about $148.5K of REPL on Aug 10, 2026; 3 other insiders sold within 30 days and 145 funds added in the latest 13F quarter.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on May 18, 2026.
- The trade is 5.6% of the 708,151 shares held after it.
- 3 other insiders sold within 30 days.
- 145 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Patel Sushil sold about $510.3K of REPL on Aug 10, 2026, the largest insider sale at the company since 2022; 3 other insiders sold within 30 days and 145 funds added in the latest 13F quarter.104 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$1.6M over 180 days
-$1.0M over 90 days
below 67% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
145 funds bought in last quarter
more than 81% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
34.2% of the float short (float per yahoo 2026-10-26) · 10.8 days to cover · settled 2026-09-30
more than 98% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch REPL
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+48.1%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns REPL: institutional holders (13F)
13F holdings, latest reported quarter
11,045,336 sh
$122.3M
8,958,535 sh
$99.2M
7,411,581 sh
$82.0M
7,310,656 sh
$80.9M
4,541,018 sh
$50.3M
Congress trades in REPL
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
REPL planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
REPL mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco Dorsey Wright Healthcare Momentum ETF
$4.5M position · as of 2026-07-31
1.9%
Virtus Biotech Clinical Trials Etf
$392.0K position · as of 2026-07-31
0.8%
Horizon Kinetics Medical ETF
$139.3K position · as of 2026-06-30
0.7%
State Street(R) SPDR(R) S&P(R) Biotech ETF
$30.5M position · as of 2026-06-30
0.3%
PROFUND VP BIOTECHNOLOGY
$134.8K position · as of 2026-06-30
0.3%
Artisan International Small-Mid Fund
$6.7M position · as of 2026-06-30
0.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $1.6M sold by insiders over 180 days, 145 funds added last quarter. Each figure is a federal filing, dated the day it went public.
REPL financials
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM REPL
| FY Mar 2026 | n/a |
| FY Mar 2025 | n/a |
| FY Mar 2024 | n/a |
| FY Mar 2023 | n/a |
| FY Mar 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM REPL
| FY Mar 2026 | n/a |
| FY Mar 2025 | n/a |
| FY Mar 2024 | n/a |
| FY Mar 2023 | n/a |
| FY Mar 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$280.5M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM REPL
| FY Mar 2026 | -$284.6M |
| FY Mar 2025 | -$198.9M |
| FY Mar 2024 | -$191.1M |
| FY Mar 2023 | -$130.3M |
| FY Mar 2022 | -$84.5M |
| Jun 2026 | -$75.7M |
| Mar 2026 | -$56.2M |
| Dec 2025 | -$66.1M |
| Sep 2025 | -$82.6M |
| Jun 2025 | -$79.8M |
| Mar 2025 | -$54.9M |
| Dec 2024 | -$52.5M |
| Sep 2024 | -$40.7M |
At each fiscal year end
Single quarter
Debt to equity
0.80x
long-term debt only, 2026-06-30; equity 2026-06-30
Debt to equity REPL
| FY Mar 2026 | 0.50x |
| FY Mar 2025 | 0.11x |
| FY Mar 2024 | 0.12x |
| FY Mar 2023 | 0.05x |
| FY Mar 2022 | 0.00x |
| Jun 2026 | 0.80x |
| Mar 2026 | 0.50x |
| Dec 2025 | 0.23x |
| Sep 2025 | 0.18x |
| Jun 2025 | 0.14x |
| Mar 2025 | 0.11x |
| Dec 2024 | 0.10x |
| Sep 2024 | 0.12x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-3.32x
TTM operating cash flow over long-term debt only, 2026-06-30
Cash flow to debt REPL
| FY Mar 2026 | -3.37x |
| FY Mar 2025 | -4.15x |
| FY Mar 2024 | -4.14x |
| FY Mar 2023 | -4.47x |
| FY Mar 2022 | n/a |
| Jun 2026 | -3.32x |
| Mar 2026 | -3.37x |
| Dec 2025 | -5.84x |
| Sep 2025 | -5.56x |
| Jun 2025 | -4.70x |
| Mar 2025 | -4.15x |
| Dec 2024 | -4.02x |
| Sep 2024 | -3.97x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-134.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity REPL
| FY Mar 2026 | -107.9% |
| FY Mar 2025 | -62.6% |
| FY Mar 2024 | -46.4% |
| FY Mar 2023 | -36.1% |
| FY Mar 2022 | -25.9% |
| Jun 2026 | -134.3% |
| Mar 2026 | -107.9% |
| Dec 2025 | -90.9% |
| Sep 2025 | -96.2% |
| Jun 2025 | -73.4% |
| Mar 2025 | -62.6% |
| Dec 2024 | -50.5% |
| Sep 2024 | -50.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-82.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets REPL
| FY Mar 2026 | -71.0% |
| FY Mar 2025 | -47.6% |
| FY Mar 2024 | -38.0% |
| FY Mar 2023 | -31.5% |
| FY Mar 2022 | -23.5% |
| Jun 2026 | -82.3% |
| Mar 2026 | -71.0% |
| Dec 2025 | -67.2% |
| Sep 2025 | -69.9% |
| Jun 2025 | -55.8% |
| Mar 2025 | -47.6% |
| Dec 2024 | -40.2% |
| Sep 2024 | -40.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital REPL
| FY Mar 2026 | n/a |
| FY Mar 2025 | n/a |
| FY Mar 2024 | n/a |
| FY Mar 2023 | n/a |
| FY Mar 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-95.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed REPL
| FY Mar 2026 | -83.8% |
| FY Mar 2025 | -55.9% |
| FY Mar 2024 | -44.3% |
| FY Mar 2023 | -33.6% |
| FY Mar 2022 | -24.4% |
| Jun 2026 | -95.4% |
| Mar 2026 | -83.8% |
| Dec 2025 | -77.7% |
| Sep 2025 | -80.9% |
| Jun 2025 | -64.8% |
| Mar 2025 | -55.9% |
| Dec 2024 | -45.9% |
| Sep 2024 | -47.4% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing REPL
| FY Mar 2026 | n/a |
| FY Mar 2025 | n/a |
| FY Mar 2024 | n/a |
| FY Mar 2023 | n/a |
| FY Mar 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$1.1B
market value at close 2026-10-26 on 2026-08-11 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
Enterprise value REPL
| FY Mar 2026 | $506.0M |
| FY Mar 2025 | $686.2M |
| FY Mar 2024 | $471.9M |
| FY Mar 2023 | $882.6M |
| FY Mar 2022 | $695.7M |
| Jun 2026 | $828.0M |
| Mar 2026 | $506.0M |
| Dec 2025 | $687.1M |
| Sep 2025 | $272.0M |
| Jun 2025 | $665.6M |
| Mar 2025 | $686.2M |
| Dec 2024 | $702.3M |
| Sep 2024 | $680.9M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-23.9%
TTM free cash flow over market value at close 2026-10-26
FCF yield REPL
| FY Mar 2026 | -45.0% |
| FY Mar 2025 | -26.5% |
| FY Mar 2024 | -38.1% |
| FY Mar 2023 | -13.0% |
| FY Mar 2022 | -10.5% |
| Jun 2026 | -30.2% |
| Mar 2026 | -45.0% |
| Dec 2025 | -37.2% |
| Sep 2025 | -82.5% |
| Jun 2025 | -31.8% |
| Mar 2025 | -26.5% |
| Dec 2024 | -23.2% |
| Sep 2024 | -25.1% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing REPL
| FY Mar 2026 | n/a |
| FY Mar 2025 | n/a |
| FY Mar 2024 | n/a |
| FY Mar 2023 | n/a |
| FY Mar 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2026-03 | 2025-03 | 2024-03 | 2023-03 | |
|---|---|---|---|---|
| Operating income | -$319.9M | -$261.6M | -$234.8M | -$177.1M |
| Net income | -$313.9M | -$247.3M | -$215.8M | -$174.3M |
| EPS (diluted) | -3.38 | -3.07 | -3.24 | -2.99 |
| Operating cash flow | -$280.3M | -$192.2M | -$185.5M | -$128.1M |
| Cash | $209.0M | $111.1M | $74.5M | $146.6M |
| Long-term debt | $83.3M | $46.4M | $44.8M | $28.6M |
SEC XBRL, fiscal years, as known on 2026-10-28
REPL Stock Sonar score 5/7 axes
Find similar shapesCompareREPL ranks highest on institutional and government (81st percentile) and risk and compliance (32nd), and lowest on insider conviction (15th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
REPL filings, in plain words
Are Replimune insiders buying or selling REPL?
In the 180 days to 2026-10-28, Replimune insiders were net sellers, a net $1.6M across purchases and sales reported on Form 4, by 6 sellers.
Read the full summary
In the 180 days to 2026-10-28, Replimune insiders were net sellers of REPL, a net $1.6M across purchases and sales reported on Form 4 by 6 sellers. None of the 12 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
